secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001558370-23-002685
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio reports FY2022 net loss $88.2M; cash $120.4M; XTX202 shows early tumor-selective activation
--------------------------------------------------------------------------------

- Cash and cash equivalents $120.4M as of Dec 31, 2022, down from $198.1M; cash runway into Q2 2024.
- Net loss for FY2022 was $88.2M vs $75.8M in 2021; Q4 net loss $22.5M vs $19.7M.
- XTX202 (tumor-activated IL-2) showed preliminary pharmacodynamic evidence of tumor-selective activation in two patients; no vascular leak syndrome observed.
- XTX202 Phase 2 monotherapy trial in melanoma and RCC to initiate April 2023; preliminary Phase 1/2 data expected Q3 2023.
- XTX101 (anti-CTLA-4) RP2D set at 150 mg Q6W; preliminary Phase 1 data expected Q2 2023; exploring partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023002685/0001558370-23-002685-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837023002685/xlo-20230302x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-002685

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer